Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double Blind (Sponsor Unblinded), Single and Repeat Ascending Dose First Time in Human Study in Healthy Subjects, Cold Urticaria and Chronic Spontaneous Urticaria Subjects to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264

NCT02424799 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02424799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02424799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double Blind (Sponsor Unblinded), Single and Repeat Ascending Dose First Time in Human Study in Healthy Subjects, Cold Urticaria and Chronic Spontaneous Urticaria Subjects to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
November 17, 2014
Completion date
November 10, 2017
Enrollment
34 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

urticaria